Navigation Links
Ruboxistaurin As A Novel Treatment For Diabetic Nephropathy

Recent research, which appears in the current issue of Diabetes Care, establishes Ruboxistaurin as a promising novel treatment that may improve upon established therapies for diabetic nephropathy//.

Nephropathy is known to develop in 40% of people with type 2 diabetes and is the leading cause of end-stage renal disease in the U.S. and the developed world.

Many persons with diabetes have progressive nephropathy even with the established therapies. Therefore, treatments targeting novel pathogenic mechanisms may be beneficial.

Studies have shown an important role for protein kinase C (PKC)-? in the pathogenesis of diabetic nephropathy. Ruboxistaurin selectively inhibits protein kinase C-? and ameliorates kidney disease in animal models of diabetes.

The study was performed to evaluate the effects of 32mg/day ruboxistaurin for 1 year in persons with type 2 diabetes and persistent albuminuria persistent albuminuria (albumin-to-creatinine ratio [ACR] 200-2,000 mg/g), despite therapy with renin-angiotensin system inhibitors. The primary end point was a change in the ACR. Estimated glomerular filtration rate (eGFR) was also calculated.

It was found that after one year, urinary ACR decreased significantly in participants treated with ruboxistaurin and nonsignificantly in the placebo group. The ACR-lowering effect of ruboxistaurin appeared by 1 month. eGFR did not decline significantly in the ruboxistaurin group, whereas the placebo group lost significant eGFR over 1 year.

Between-group differences for changes in ACR and eGFR were not statistically significant, but this pilot study was underpowered to determine such differences.

The study authors conclude that ruboxistaurin had favorable effects on albuminuria and renal function in persons with type 2 diabetes and nephropathy. The albuminuria-lowering effect occurred early and was sustained long term. Those treated with ruboxista urin did not experience a significant decline in renal function. Ruboxistaurin may thus add benefit to established therapies for diabetic nephropathy. The authors suggest that large-scale trials should be performed to confirm its effectiveness and safety.
'"/>




Related medicine news :

1. Ruboxistaurin (RBX) may prevent vision loss in diabetic patients
2. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
3. Novel biopsy technique for prostate cancer
4. Novel computer model for breast cancer
5. Novel research on liver cancer
6. Novel way to fight cancer
7. Novel test for bowel cancer
8. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
9. Novel Therapy for Chronic Problem
10. Blood Sugar Kept In Control By Novel Protein
11. Novel antibiotic dressing developed for improved wound healing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of ... announced today its plans to open a flagship location in Covington, LA at 401 ... Rooms To Go store next to Office Depot in the Holiday Square shopping center. ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
Breaking Medicine Technology: